Energenesis Biomedical Co., Ltd.
Climate Impact & Sustainability Data (2021-2022, 2022)
Reporting Period: 2021-2022
Environmental Metrics
Total Carbon Emissions:Not disclosed
Scope 1 Emissions:Not disclosed
Scope 2 Emissions:Not disclosed
Scope 3 Emissions:Not disclosed
Renewable Energy Share:Not disclosed
Total Energy Consumption:Not disclosed
Water Consumption:Not disclosed
Waste Generated:Not disclosed
Carbon Intensity:Not disclosed
ESG Focus Areas
- Corporate Governance
- Environmental Risk Management
- Social Responsibility
- Supply Chain Management
Environmental Achievements
- Not disclosed
Social Achievements
- Annual employee health checkups, group insurance, company trips, birthday celebrations; established employee stock ownership plan, employee welfare plan, employee bonus plan, labor retirement plan, and employee sports plan.
Governance Achievements
- Board attendance rate of 98.81% in 2021 and 2022; 100% attendance rate for Audit Committee and Remuneration Committee in 2021 and 2022; established Code of Conduct, Code of Ethics, and Insider Trading Prevention Management Procedures.
Climate Goals & Targets
Long-term Goals:
- Not disclosed
Medium-term Goals:
- Not disclosed
Short-term Goals:
- Not disclosed
Environmental Challenges
- Not disclosed
Mitigation Strategies
- Not disclosed
Supply Chain Management
Supplier Audits: Not disclosed
Responsible Procurement
- Supplier Management Procedures, Corporate Social Responsibility Practices, Code of Conduct
Climate-Related Risks & Opportunities
Physical Risks
- Not disclosed
Transition Risks
- Not disclosed
Opportunities
- Not disclosed
Reporting Standards
Frameworks Used: Null
Certifications: Null
Third-party Assurance: Not disclosed
UN Sustainable Development Goals
- Not disclosed
Not disclosed
Sustainable Products & Innovation
- Not disclosed
Awards & Recognition
- Not disclosed
Reporting Period: 2022
Environmental Metrics
Social Achievements
- Implemented employee welfare measures including share options, birthday celebrations, performance bonuses, travel subsidies, training subsidies, group insurance, health checkups, and sports subsidies.
- Maintained amicable employer-employee relations with no major disputes.
Governance Achievements
- Established a Remuneration Committee and an Audit Committee, both composed of independent directors.
- Implemented a robust corporate governance framework, including policies and procedures for various aspects of corporate governance.
- Completed self-evaluations for the performance of its Board of Directors, individual board members, Audit Committee, and Remuneration Committee in 2022.
Climate Goals & Targets
Long-term Goals:
- Introduce potential candidate drugs through academic solicitation.
Medium-term Goals:
- Seek strategic partners to jointly develop pre-clinical new drugs.
- Reinforce patent deployment and explore international authorization opportunities.
Short-term Goals:
- Conduct global Phase 3 clinical trials of F703 and seek talks with international pharmaceutical companies.
- Finish preparations for Phase 1 clinical trials of F705.
- Seek talks with international pharmaceutical companies or cosmetics manufacturers for F701 commercialization.
Environmental Challenges
- Global pandemic impacting net business revenue.
- Increased expenditure on Phase 3 clinical trial of ENERGI-F703 and preparations for Phase 1 clinical trial of ENERGI-F705 leading to after-tax deficits.
- Increasing competition in new drug development driving down prices.
Mitigation Strategies
- Proactively approaching international pharmaceutical companies for capital through authorization and creating a value chain featuring phased profits.
- Focusing on new indications in research and development under patented ENERGI to increase clinical trial success rate, reduce R&D time and budget, and lower risk.
- Seeking strategic partners for joint development of pre-clinical new drugs.
- Reinforcing patent deployment and exploring opportunities for international authorization of new drugs.
- Introducing potential candidate drugs through academic solicitation.
- Purchasing USD fixed deposits to reduce exchange rate risk.
Supply Chain Management
Responsible Procurement
- The Company chooses to collaborate with well-reputed suppliers through fair and transparent methods, protecting the rights and interests of both parties.
Climate-Related Risks & Opportunities
Awards & Recognition
- 17th National Industrial Innovation Award - Corporate Innovation in the biotech pharmaceutical and precision medicine category